Equities analysts predict that Ascendis Pharma (NASDAQ:ASND) will announce earnings of ($0.93) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Ascendis Pharma’s earnings, with the lowest EPS estimate coming in at ($1.05) and the highest estimate coming in at ($0.72). Ascendis Pharma posted earnings of ($0.83) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 12%. The firm is expected to issue its next quarterly earnings report on Tuesday, May 22nd.
According to Zacks, analysts expect that Ascendis Pharma will report full year earnings of ($3.83) per share for the current fiscal year, with EPS estimates ranging from ($4.29) to ($2.89). For the next year, analysts anticipate that the business will post earnings of ($2.98) per share, with EPS estimates ranging from ($4.98) to $1.15. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Ascendis Pharma.
Several equities research analysts recently issued reports on the company. ValuEngine raised Ascendis Pharma from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Wedbush reissued a “top pick” rating and set a $76.00 price objective on shares of Ascendis Pharma in a research note on Friday, April 20th. Leerink Swann reissued a “market perform” rating and set a $64.00 price objective (up previously from $37.00) on shares of Ascendis Pharma in a research note on Monday, April 2nd. JPMorgan Chase lifted their price objective on Ascendis Pharma to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, March 21st. Finally, Credit Suisse Group lifted their price objective on Ascendis Pharma from $50.00 to $78.00 and gave the company an “outperform” rating in a research note on Tuesday, March 20th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $67.33.
NASDAQ:ASND traded down $0.13 during trading hours on Monday, hitting $65.28. 35,316 shares of the company’s stock traded hands, compared to its average volume of 169,561. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of -15.08 and a beta of 0.65. Ascendis Pharma has a 52 week low of $21.95 and a 52 week high of $69.00.
About Ascendis Pharma
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.